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Abstract
The large plasmid pXO1 encoding the anthrax toxin is important for the virulence of Bacillus anthracis. It is essential to cure
pXO1 from B. anthracis to evaluate its role in the pathogenesis of anthrax infection. Because conventional methods for
curing plasmids (e.g., curing agents or growth at elevated temperatures) can induce mutations in the host chromosomal
DNA, we developed a specific and reliable method to eliminate pXO1 from B. anthracis using plasmid incompatibility. Three
putative replication origins of pXO1 were inserted into a temperature-sensitive plasmid to generate three incompatible
plasmids. One of the three plasmids successfully eliminated the large plasmid pXO1 from B. anthracis vaccine strain A16R
and wild type strain A16. These findings provided additional information about the replication/partitioning of pXO1 and
demonstrated that introducing a small incompatible plasmid can generate plasmid-cured strains of B. anthracis without
inducing spontaneous mutations in the host chromosome.
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Introduction
Bacillus anthracis, a gram-positive, rod-shaped, spore-forming
bacterium, is the etiologic agent of anthrax, an acute and often
fatal mammalian disease [1,2,3]. Virulent forms of B. anthracis
harbor two large pathogenicity-related plasmids: pXO1
(181.6 kb), which encodes the anthrax toxin genes pagA, lef, and
cya [2,4]; the toxin regulatory elements atxA and pagR; the plasmid-
borne germination genes gerXC,- A, and -B [2,4,5,6]; and pXO2
(93.5 kb), which carries the genes responsible for capsule synthesis
and degradation, capA, -B, -C and -D [7,8,9,10,11]. The two large
plasmids of B. anthracis are essential for full pathogenicity;
elimination of either dramatically attenuates the virulence of B.
anthracis.
Numerous studies have attempted to characterize the role of
these plasmids in virulence. Generating a plasmid-free strain is
important to elucidate the crosstalk between the plasmids and host
chromosome. Conventional curing strategies involve chemical
agents (e.g., acridine orange, novobiocin, ethidium bromide),
growth at elevated temperature, or treatment with ultraviolet (UV)
light [12,13,14,15,16]. These strategies have been used successfully
in many bacteria to eliminate resident plasmids. However, these
methods are not specific to a particular plasmid but eliminate all
resident plasmids. Furthermore, elimination of the resident
plasmids is spontaneous; therefore, screening colonies for plas-
mid-cured strains is a tedious process. Finally, most known
plasmid-curing chemical agents are toxic or mutagenic (e.g.,
acridine orange, ethidium bromide, and sodium dodecyl sulfate)
and can therefore induce mutations in the host chromosome [17].
Mutations also occur during harsh physical curing treatments (e.g.,
high temperature or UV light). The phenotypic changes caused by
mutation may interfere with the functional analysis of the plasmid
[18]. For these reasons, there is a need to develop a curing method
that is safe, reliable, and specific to the plasmid of interest.
Plasmid incompatibility is the inability of two different but
related plasmids to coexist stably in the same host cell in the
absence of continued selective pressure. Plasmids that share the
same mechanisms for replication or partitioning are placed in the
same incompatibility group. Plasmid incompatibility may be due
to competition for the same replication or segregation sites, or
caused by the repression of replication initiation [19]. Thus,
introducing a smaller high-copy-number plasmid from the same
incompatibility group may specifically eliminate a resident
plasmid. This strategy has been demonstrated to be a specific,
efficient, and safe technique to generate plasmid-free bacterial
strains [20,21].
Tinsley et al. isolated and characterized a minireplicon of
plasmid pXO2 [22]. These researchers cloned a 2429-bp region of
pXO2 into an Escherichia coli vector that is normally unable to
replicate in B. anthracis, and demonstrated that this plasmid
replicated when introduced into B. anthracis. The pXO2 replicon
contains an open reading frame (ORF) encoding the putative
replication initiation protein RepS and the putative origin of
replication ori. Another ORF (repB) was included in this fragment
but thought to be dispensable for replication of the pXO2
minireplicon [22]. Based on this information, we successfully cured
the large pXO2 plasmid from the B. anthracis wild type strain A16
(pXO1
+pXO2
+) using a smaller plasmid in which a 3836-bp
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inserted [23]. These results initiated our interest in eliminating the
plasmid pXO1 fromB.anthracis using plasmid incompatibility,which
has not yet been reported in the literature. Little is known about the
replication and partition properties of pXO1. The origin of
replication and genes involved in replication initiation, plasmid
partitioning, and plasmid stability have not been identified.
Researchers have long sought to characterize the structure of the
pXO1replicon.Robertsonetal.attemptedtolocalizethereplication
origin by cloning pXO1 DNA fragments into an E. coli vector and
transforming the plasmid into B.subtilis. Thisgroupidentified several
clonesthat mappedtoan11-kb region (coordinates 86249–97209)of
the pXO1 sequence (GenBank accession no. AF065404; ORF72-
81) (coordinate numbers and ORFs annotated by Okinaka et al. will
be used throughout this report) [24]. The products encoded by the
10 ORFs did not show any sequence similarity to rep proteins
associated with theta-replicating plasmids. In the past 10 years, data
from numerous B. anthracis genome-sequencing projects have
considerably increased our understanding of the biological roles of
plasmids in this species. Plasmid pXO1 of the B. anthracis Sterne
strain was sequenced by Okinaka et al. using a random whole-
genome shotgun strategy, which enabled analysis of its replicon. The
annotation predicted 143 ORFs in pXO1, but only 35 have putative
functions assigned to them based on similarity to genes in open
databases. Unfortunately, no sequences have been found that show
significant similarity with known replication initiator proteins
encoded by other plasmids [24]. Tinsley and Khan cloned a 5-kb
region (ORF43–46, nt 54863–60166) of the plasmid pXO1 into an
E.colivectorand demonstrated that this plasmid couldreplicateinB.
anthracis. Mutational analysis showed that ORF45 was required for
replication of the minireplicon, and this ORF was designated repX
[25]. In a more recent effort to understand pXO1 replication,
Andrei et al. isolated and characterized a new minireplicon of B.
anthracis plasmid pXO1 using the Cre-loxP recombination system
to delete large DNA segments; this region (ORF14–16, nt 19032–
24981) differed from those previously described. Deletion analysis
showed that only ORF14 and ORF16 were essential for
replication of the minireplicon, and ORF16 was thought to be
the replication initiator protein with a putative theta-replicating
origin of replication [26].
In this report, we cured the virulence-associated plasmid pXO1
from B. anthracis vaccine strain A16R and wild type strain A16,
using plasmid incompatibility to generate isogenic plasmid-cured
and plasmid-containing strains. Our results will lead to a better
understanding of the pXO1 plasmid and its interaction with the B.
anthracis chromosome.
Materials and Methods
Bacterial Strains, Plasmids, and Culture
The bacterial strains and plasmids used in this study are listed in
Table 1. B. anthracis A16 strain was isolated from the carcass of a
mule that had died of anthrax in Langfang city in the Hebei
province of China in 1953. The lethal dose of A16 is 100 spores for
mice and 150 spores for rabbits administered by subcutaneous
injection. B. anthracis vaccine strain A16R was derived from A16
by exposure to UV radiation. A culture dish containing the spore
suspension of A16 was placed 10 cm from the center of a UV
lamp. After a 3-hour UV treatment, the irradiated suspension was
spread on agar plates containing 20% bovine serum and incubated
in 20% CO2 at 37uC for 24 hours. A rough colony was chosen to
streak on an agar plate containing 20% bovine serum, which was
incubated in 20% CO2 at 37uC for 24 hours. This procedure was
repeated until all descendants produced rough colonies. One of
these clones was carried continuously in nutrient medium for 141
passages and in mice for 30 generations. With no descendants
producing smooth colonies, this clone was considered stable and
designated A16R. Its virulence was greatly attenuated, primarily
through loss of the bacterial capsule, and A16R is now used for the
human anthrax vaccine in China. For safety reasons and ease of
handling in the laboratory, an attenuated B. anthracis vaccine strain
A16R (pXO1+ pXO22) was used for the initial experiments in
the present study. The experiments were then repeated with the
wild type strain A16. The temperature-sensitive shuttle vector
pKSV7 (permissive temperature, 30uC; restrictive temperature,
37uC) contains a chloramphenicol resistance gene for selection in
B. anthracis, an ampicillin resistance gene for selection in E. coli, and
a multiple cloning site [27]. Strains containing recombinant
plasmids were cultured at 30uC, except when curing the plasmid
from the host bacteria, when the strains were cultured at 37uC.
Table 1. Plasmids and bacterial strains used in this study.
Plasmids and strains Relevant genotype and characteristics Source
pKSV7 Shuttle vector, temperature-sensitive, Amp
r (gram-negative) in E. coli and Cm
r
(gram-positive) in B. anthracis
[27]
pKS4K Incompatible plasmid, constructed by inserting 4-kb fragment of pXO1 into pKSV7 This work
pKS5K Incompatible plasmid, constructed by inserting 5-kb fragment of pXO1 into pKSV7 This work
pKS11K Incompatible plasmid, constructed by inserting 11-kb fragment of pXO1 into pKSV7 This work
E. coli DH5a F
2, Q80d/lacZDM15, D(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk
2,mk
+), phoA,
supE44l
2, thi-1, gyrA96, relA1
This lab
E. coli SCS110 rpsL(StrR), thr, leu, endA, thi-1, lacy, galK, galT, ara, tonA, tsx, dam-, dcm-,
supE44(lac-proAB), F- [traD36, proAB, lacIqlacZDM15]
This lab
B. anthracis A16R Vaccine strain, pXO1
+, pXO2
2 This lab
B. anthracis A16 Wild type A16R; pXO1
+, pXO2
+ This lab
B. anthracis A16R5K A16R was cured of pXO1, harbors recombinant plasmid pKS5K; pXO1
2, pXO2
2,
pKS5K
+
This work
B. anthracis A16RO pXO1 plasmid-cured derivative of vaccine strain A16R; pXO1
2, pXO2
2 This work
B. anthracis A16Q1 pXO1 plasmid-cured derivative of wild type A16; pXO1
2,p X O 2
+ This work
doi:10.1371/journal.pone.0029875.t001
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were passaged through E. coli SCS110 (dam dcm mutant) to
demethylate the plasmid DNA, thereby facilitating its transforma-
tion into bacteria. All strains were cultured in Luria-Bertani (LB)
broth (10 g/L tryptone [Oxoid, UK], 5 g/L yeast extract [Oxoid],
10 g/L NaCl) or on LB agar plates. Transformants were selected
for ampicillin resistance (100 mg/mL) in E. coli or for chloram-
phenicol resistance (10 mg/mL) in B. anthracis.
Construction of Incompatible Plasmids
Based on the literature, we evaluated three DNA fragments (11-
kb, 4-kb, and 5-kb) containing putative replication origins of
pXO1 (Figure 1). The vector pKSV7 was linearized at the SmaI
restriction site with restriction enzyme (TaKaRa Biotechnology,
Dalian, China) and purified after 0.6% agarose gel electrophoresis
using an agarose gel DNA purification kit. The 4-kb and 5-kb
fragments were amplified with Pyrobest DNA polymerase
(TaKaRa Biotechnology,Dalian, China) by polymerase chain
reaction (PCR) from the total genomic DNA of strain A16R with
the primer pairs 4K_F/R and 5K_F/R, respectively. The
resulting fragments were cloned directly into the linearized
pKSV7 vector by homologous recombination using the CloneEZ
kit (GenScript, Piscataway, NJ, USA), generating the plasmids
pKS4K and pKS5K, respectively. The 11-kb fragment was
amplified by PCR from total DNA of strain A16R with the three
primer pairs 11K_1F/R, 11K_2F/R, and 11K_3F/R. These
PCR products were purified with the QIAquick PCR purification
kit (Qiagen, Germany) and cloned in tandem into the linearized
pKSV7 vector to generate pKS11K. PCR was performed in a
100-mL reaction containing 1 mL Pyrobest DNA polymerase,
10 mL1 0 6polymerase buffer, 8 mL dNTP mixture, 2 mL template
DNA, 2 mL each primer (Table S1), and 75 mL double-distilled
H2O (ddH2O). PCR amplification was carried out in a GeneAmp
PCR System 9700 (Applied Biosystems, Carlsbad, CA, USA) with
an initial denaturation step at 94uC for 5 min, followed by 30
cycles of 94uC for 40 s, 55uCt o5 8 uC for 40 s, 72uC for 4 to
6 min, and a final extension step at 72uC for 5 min. Clones were
generated by homologous recombination with the CloneEZ kit
(GenScript) according to the manufacturer’s instructions.
The plasmids pKS4K, pKS5K, and pKS11K were introduced
into chemically competent E. coli DH5a cells. The samples were
grown at 30uC for 3 h in fresh LB broth without antibiotics on a
shaker (225 rpm) and then spread onto selective agar plates
containing ampicillin. After incubation at 30uC for 12 to 16 h,
transformants were picked and analyzed by colony PCR. Briefly, a
single colony was suspended in 100 mL ddH2O, heated to 95uC for
2 min, and then cooled to room temperature. Cellular debris was
removed by centrifugation at 15,0006g for 5 min, and 1 mL of the
lysate was used as template for PCR amplification. PCR was
performed in a 20-mL reaction containing 10 mL2 6 Taq PCR
Master Mix, 1 mL template, 7 mL ddH2O, and 1 mL each primer.
The primer pair pKSV7-F/R, which flanks the multiple cloning
site, was used to determine whether the 4-kb or 5-kb DNA
fragment were inserted into pKSV7, and three primer pairs
(11K_1F/R, 11K_2F/R and 11K_3F/R) were used to determine
whether the 11-kb DNA fragment was inserted (Table S1). The
thermal cycling conditions used to analyze transformants were
same as those used to amplify fragments from the A16R total
genomic DNA. Colonies that were positive for transformation, as
assessed by colony PCR analysis, were analyzed by restriction
digestion and DNA sequencing in an ABI Prism Model 3730XL
DNA analyzer (Applied Biosystems). The recombinant plasmids
pKS4K, pKS5K, and pKS11K were confirmed by sequencing
and introduced into the dam
2 dcm
2 E. coli host strain SCS110 by
electroporation (200 V,2 5mF, 1.8 kV) (Bio-Rad Gene Pulser II
electroporator, Hercules, CA, USA) to obtain demethylated
plasmid DNA for transformation into the B. anthracis A16R strain.
Curing of Plasmid pXO1 from B. anthracis A16R Strain
The electroporation-competent B. anthracis A16R cells were
prepared as previously described [28]. The plasmids pKS4K,
pKS5K, and pKS11K were isolated (Axygen Scientific, Union
City, CA, USA) from E. coli SCS110 and introduced into B.
anthracisA16R by electroporation (500 V,2 5mF, 0.6 kV). The cells
were grown at 30uC for 3 h in LB broth without antibiotics on a
shaker (200 rpm) and then spread onto chloramphenicol-contain-
ing agar plates. After incubation at 30uC for 18 to 22 h,
transformants were analyzed by colony PCR. Positive clones were
selected and designated pKS4K/A16R (pXO1
+pXO2
2pKS4K
+),
pKS5K/A16R (pXO1
+pXO2
2pKS5K
+), and pKS11K/A16R
(pXO1
+pXO2
2pKS11K
+), respectively. The three clones were
passaged separately at least five times in 5 mL LB broth con-
taining chloramphenicol (30uC, 225 rpm) for 12 h. At each
passage, aliquots of each culture were diluted and spread on
Figure 1. Three putative replicons of plasmid pXO1 (GenBank Accession no. AF065404). Each putative replicon of pXO1 is indicated in a
different color, along with primer pairs used for amplification.
doi:10.1371/journal.pone.0029875.g001
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analyzed by colony PCR to determine the elimination of pXO1
from B. anthracis A16R using three pairs of primers (pag-F/R, lef-
F/R, and cya-F/R) (Table S1). Putative pXO1-cured clones were
selected, and genomic DNA was purified with TIANamp Bacteria
DNA kit (Tiangen Biotech, Beijing, China) according to the
manufacturer’s instructions for isolating genomic DNA from
gram-positive bacteria. To ensure the elimination of pXO1 from
the A16R strain, 14 different pXO1 genes were analyzed by PCR
using the total genomic DNA from strain A16R and the putative
pXO1-cured clones as templates (Table S1).
Elimination of Extraneous Plasmid pKS5K from Strain
A16R5K (pXO1
2pXO2
2pKS5K)
To obtain a plasmid-cured strain without exogenous DNA, we
needed to eliminate the recombinant plasmid from the host A16R
strain. The pXO1-cured A16R strain containing the incompatible
plasmids was passaged more than six times in 5 mL LB broth
without antibiotics at 37uC for 12 h on a shaker (225 rpm). At
each passage, aliquots of the cultures were diluted and spread on
agar plates without antibiotics and incubated at 37uC for 12 h.
Single clones were streaked onto two agar plates with or without
chloramphenicol. The agar plates were incubated at 30uC
overnight, and chloramphenicol-sensitive clones were considered
positive for loss of the incompatible plasmid. The DNA of these
clones was extracted and used as template for PCR with two
primer pairs specific to plasmid pKSV7 (pKSV7P3_F/R and
pKSV7P6_F/R, Table S1) to verify elimination of the incompat-
ible plasmid.
Detection of Anthrax Toxin Protective Antigen by
Western Blot Analysis
Western blot analysis was performed to verify the curing of
pXO1 from B. anthracis A16R. The A16R strain (pXO1
+
pXO2
2) and A16R derivative strain (pXO1
2 pXO2
2)w e r e
cultured on LB agar supplemented with 5% horse serum and
0.9% sodium bicarbonate at 37uCi n5 %C O 2 for 12 h. The
bacteria were collected, and the cell suspension was separated
by 12% bis-polyacrylamide gel electrophoresis. Proteins were
transferred with Hoefer TE 77 semi-dry transfer unit (Amer-
sham Bioscience, USA) from the gel to a polyvinylidene fluoride
membrane with a constant current of 35 mA for 1 h 50 min.
The transferred membrane was blocked with Tris buffered
saline with 0.05% Tween 20 (TBST) containing 5% skim milk
and then incubated with the mouse monoclonal antibody
against protective antigen (C3; Santa Cruz, CA, USA) diluted
in TBST (1:500) for 60 min at room temperature. After washing
three times with TBST for 7 min, the membrane was incubated
in 40 ml TBST with goat anti-mouse IgG conjugated to
horseradish peroxidase (HRP) (1:10000) (Santa Cruz) for
60 min, and then washed four times with TBST for 7 min.
The membrane was immersed in ECL substrate solution
(Thermo Scientific, USA) for 5 min, and then exposed to x-
r a yf i l m( K o d a kR PX - O M A T ,U S A ) .
Use of Plasmid Incompatibility to Cure pXO1 from Wild
Type Strain A16
The plasmid used to cure pXO1 from B. anthracis vaccine strain
A16 was introduced into B. anthracis wild type strain A16 to cure
the plasmid pXO1 using the same methods described above.
Bacterial capsules were stained with India ink (Gibco, USA) and
observed with a phase-contrast microscope (Eclipse TE300,
Nikon, Tokyo, Japan).
Results
Identification of Incompatible Plasmids
Colony PCR was performed to screen for transformants of the
incompatible plasmids, and plasmids were isolated from the
positive clones. Restriction analysis confirmed insertion of the 4-
kb, 5-kb, and 11-kb DNA fragments into the vector pKSV7. The
recombinant plasmids were confirmed by DNA sequencing and
designated pKS4K, pKS5K, and pKS11K, respectively. These
plasmids were introduced into B. anthracis to cure plasmid pXO1
from A16R.
Elimination of pXO1 from A16R by Plasmid
Incompatibility
The recombinant plasmids pKS4K, pKS5K, and pKS11K
were introduced into B. anthracis vaccine strain A16R and passaged
10 times in chloramphenicol-containing LB. The cultures were
plated on selective LB agar plates containing chloramphenicol,
and colony PCR was performed with the three pairs of specific
primers (pag_F/R, lef_F/R, and cya_F/R) to screen for pXO1-
cured colonies (Figure 2). Positive colonies underwent further PCR
analysis using 14 pairs of specific primers to confirm the
elimination of pXO1 from A16R. None of the primers specific
to plasmid pXO1 amplified DNA from the A16R colonies
transformed with pKS5K (Figure 3). These results demonstrate
the elimination of pXO1 from B. anthracis A16R by the
incompatible plasmid pKS5K. The pXO1-cured A16R derivative
strain was designated A16R5K (pXO1
2pXO2
2pKS5K
+). In
contrast, the recombinant plasmids pKS4K and pKS11K did
Figure 2. Colony PCR screening for pXO1 elimination with three plasmid-specific primer pairs. Results of using recombinant plasmids
pKS11K (A), pKS4K (B), and pKS5K (C) to eliminate the large plasmid pXO1 from B. anthracis vaccine strain A16R by plasmid incompatibility. The
presence of anthrax toxin genes pagA, lef, and cya was determined by PCR analysis of the vaccine strain A16R (1) and the putative pXO1-cured strain
A16R (2). M, DNA marker IV (Real-Times Biotechnology, Beijing, China).
doi:10.1371/journal.pone.0029875.g002
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months in chloramphenicol-containing LB broth.
Elimination of Exogenous Plasmid pKS5K from A16RK5
(pXO1
2pXO2
2pKS5K
+)
After curing pXO1 from A16R, we needed to eliminate the
exogenous plasmid pKS5K from the host bacteria. To avoid
damage to the chromosomal DNA of A16R, the bacteria
containing pKS5K were passaged five times in LB broth without
antibiotic at 37uC. The culture was plated on LB agar without
antibiotics, and single clones were screened by colony PCR with
two primer pairs (pKSV7P3_F/R and pKSV7P6_F/R) specific to
vector pKSV7. The pXO1-cured A16R derivative strain
(A16R5K) and the candidate clones were analyzed by PCR to
confirm elimination of the recombinant plasmid pKS5K. The
predicted DNA fragments were amplified from DNA of A16R5K,
but not from DNA of the candidate clones. These results indicate
that the recombinant plasmid pKS5K was successfully eliminated
from A16R5K, and this strain was named A16RO
(pXO1
2pXO2
2) (Figure 4).
Phenotypic Confirmation of A16RO (pXO1
2pXO2
2)
To confirm elimination of pXO1 from strain A16RO, the
presence or absence of the anthrax toxin protective antigen,
encoded by pXO1, was determined by western blot analysis. The
results revealed the presence of the protective antigen protein in
the cell lysate of A16R, but this protein band was not detected in
the cell lysate of A16RO, confirming that pXO1 had been
eliminated (Figure 5).
Use of Plasmid pKS5K to Cure pXO1 from Wild Type
Strain A16 (pXO1
+pXO2
+)
The results of PCR analysis and western blot analysis of the
protective antigen demonstrated that pXO1 was successfully
eliminated from B. anthracis wild type strain A16; this pXO1-cured
strain was named A16Q1 (Figure 6). Although both strains
produced capsules (Figure 6 B), the plasmid-cured strain A16Q1
did not produce the anthrax toxin protective antigen (Figure 6 C),
which was consistent with the results of PCR analysis (Figure 6 A).
Discussion
In this study, we aimed to eliminate the large plasmid pXO1
from B. anthracis using plasmid incompatibility. Although this
strategy has been used in some bacterial species to cure resident
plasmids, it has not yet been used in B. anthracis other than our
previous work to eliminate plasmid pXO2 from B. anthracis wild
type strain A16. This is mainly because the replication and
partitioning of the virulence-associated plasmids pXO1 and pXO2
are poorly understood.
Characterizing the replication origin is important to eliminate
resident plasmids from the host bacteria. However, only three
studies have described the replication and partition properties of
pXO1. Furthermore, the replication origins identified by the three
reports differed; therefore, we tested the ability of three fragments,
each containing one of the putative replication origins, to
eliminate pXO1.
Three DNA fragments containing putative origin of replication
of B. anthracis were inserted into a temperature-sensitive shuttle
vector producing the curing recombinant plasmids. One fragment
Figure 3. PCR analysis of pXO1 in B. anthracis vaccine strain A16R. PCR analysis of the vaccine strain A16R (1) and the putative pXO1-cured
strain A16R (2) with 14 primer pairs specific for plasmid pXO1. M, DNA marker IV (Real-Times Biotechnology).
doi:10.1371/journal.pone.0029875.g003
Figure 4. Elimination of exogenous plasmid pKS5K from
A16R5K. Strains A16R5K (1), and A16RO (2) were analyzed with
vector-specific primer pairs pKSV7P3_F/R and pKSV7P6_F/R. M, DNA
marker IV (Real-Times Biotechnology).
doi:10.1371/journal.pone.0029875.g004
Figure 5. Western blot analysis of A16R and A16RO. The B.
anthracis vaccine strain A16R (pX01
+ pX02
2) (left lane), A16RO
(pX01
2pX02
2) (middle lane), and anthrax toxin protective antigen
(PA) purified by affinity chromatography (right lane). The lines indicate
the location of protein bands (Blue Plus Protein Marker, TransGen
Biotechnology, Beijing, China).
doi:10.1371/journal.pone.0029875.g005
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A16R, and this result was repeated in wild type strain B. anthracis
A16. Our results suggest that replication is not initiated at the
putative pXO1 replication origins reported by Robertson et al.
[24] and Tinsley et al. [25]. Robertson et al. investigated the
replication origin of B. anthracis by transformation of a shuttle
vector containing ORF72 to ORF80 of pXO1 into B. subtilis.
However, replication of the shuttle vector in B. subtilis is not
sufficient to infer its replication in B. anthracis. Tinsley et al. cloned
several regions of plasmid pXO1 into the pBSCm plasmid of E. coli
and then introduced these recombinant plasmids into B. anthracis.
Because pBSCm is unable to replicate in B. anthracis, replication of
the recombinant plasmids in B. anthracis suggested that the DNA
fragments inserted into pBSCm contained the replication origin of
pXO1. However, DNA regions that allow pBSCm to replicate in
B. anthracis may not initiate replication of pXO1 in B. anthracis.
After deleting these regions from pXO1, the plasmid should be
tested in B. anthracis to determine whether it loses the ability to
replicate.
Our results are in agreement with those of Andrei et al. [26]
who characterized the pXO1 minimal replicon by DNA deletion.
Andrei et al. reported that deleting a 5950-bp region of pXO1
prevented replication. We successfully used a 4848-bp DNA
fragment within the 5950-bp region to cure pXO1 from B.
anthracis using plasmid incompatibility. Our findings indicate that
this fragment is the actual replication origin of plasmid pXO1.
In summary, we cured the plasmid pXO1 from B. anthracis
A16R and A16 using plasmid incompatibility. This result has
provided addition information about the replication and parti-
tioning of pXO1. In addition, we developed a specific and reliable
method to generate plasmid-cured strains of B. anthracis without
inducing spontaneous mutations in the chromosomal DNA.
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